HBIO logo

HBIO

Harvard Bioscience Inc.

$0.48
+$0.01(+1.71%)
25
Overall
--
Value
25
Tech
--
Quality
Market Cap
$21.59M
Volume
346.82K
52W Range
$0.28 - $2.82
Target Price
$2.00
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$108.7M$104.5M$77.4M$120.8M$116.2M$102.1M$118.9M$113.3M$112.3M$94.1M
Total Revenue
$108.7M$104.5M$77.4M$120.8M$116.2M$102.1M$118.9M$113.3M$112.3M$94.1M
COST OF GOODS SOLD
Cost of Revenue
$-59.9M$-56.1M$-38.2M$-57.6M$51.9M$44.1M$51.3M$52.5M$46.2M$39.4M
GROSS PROFIT
Gross Profit
$48.7M$48.4M$39.2M$63.2M$64.3M$58.0M$67.7M$60.8M$66.1M$54.8M
OPERATING EXPENSES
Operating Expenses
$-50.4M$-51.4M$-39.8M$-62.2M$62.4M$57.8M$65.6M$68.0M$64.2M$61.0M
Research & Development
$6.4M$5.4M$5.6M$11.0M$10.7M$8.7M$10.8M$12.3M$11.8M$10.4M
Research Expense
$6.4M$5.4M$5.6M$11.0M$10.7M$8.7M$10.8M$12.3M$11.8M$10.4M
Selling, General & Administrative
$40.4M$41.4M$32.6M$45.8M$46.0M$43.4M$48.9M$49.5M$46.8M$43.7M
Selling & Marketing Expenses
$20.6M$20.5M$15.1M$24.4M$23.3M$19.9M$24.6M$25.0M$24.1M$22.2M
General & Administrative Expenses
$19.8M$20.9M$17.5M$21.4M$22.8M$23.5M$24.3M$24.5M$22.8M$21.5M
Salaries & Wages
$-2.8M$-3.5M$-3.5M$-3.0M$-3.0M$-215.0K$349.0K$-420.0K$5.0M--
Depreciation & Amortization
$2.8M$2.7M$1.6M$5.4M$5.7M$5.7M$5.8M$6.1M$5.5M$5.3M
Depreciation & Amortization
$2.8M$2.7M$1.6M$5.4M$5.7M$5.7M$5.8M$6.1M$5.5M$5.3M
Amortization
$2.8M$2.7M$1.6M$5.4M$5.7M$5.7M$5.8M$6.1M$5.5M$5.3M
Other Operating Expenses
$-50.4M$-51.4M$-39.8M$-62.2M$-2.1M$-4.8M$-176.0K$-237.0K$71.0K$1.6M
OPERATING INCOME
Operating income
$-925.0K$-1.1M$-635.0K$984.0K$1.9M$221.0K$2.1M$-7.2M$1.9M$-6.2M
EBITDA
$1.9M$1.9M$1.9M$524.0K$2.7M$5.2M$9.0M$944.0K$4.7M$-4.2M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$854.0K$639.0K$713.0K$5.4M--$4.8M$1.5M$2.5M$3.6M--
Interest Income Operating
$8.0K$3.0K----------------
Intinc
$-1.9M$135.0K$-2.0M$-5.4M$-5.4M$-4.8M$-1.5M$-2.5M$-3.6M$-3.2M
Net Non-Operating Interest Income/Expense
$-854.0K$-639.0K$-713.0K$-5.4M$-5.4M$-4.8M$-1.5M$-2.5M$-3.6M$-3.2M
Gain on Sale of Securities
----------------$-632.0K$-1.6M
Other Income/Expense
$1.3M$-1.0M$739.0K$3.6M$469.0K$2.7M$666.0K$535.0K$859.0K$2.2M
Other Special Charges
$-1.3M$-179.0K$-739.0K$-3.6M$-469.0K$-2.7M$-666.0K$302.0K$-227.0K$-652.0K
SPECIAL ITEMS
Restructring And Mn A Income
$788.0K$-4.0K----$-1.4M$2.0M$1.3M$2.4M$391.0K$835.0K
Special Income Charges
$-788.0K$-672.0K$3.6M--$-1.5M$-2.0M$-1.3M$233.0K$-391.0K$-835.0K
Impairment of Capital Assets
--$676.0K----$1.5M----------
PRE-TAX INCOME
EBIT
$-2.8M$-2.4M$-1.9M$-8.0M$-5.5M$-2.5M$1.4M$-6.6M$-2.6M$-11.7M
Pre-Tax Income
$-3.6M$-3.1M$-2.6M$-8.0M$-5.5M$-7.3M$-140.0K$-9.2M$-2.6M$-11.7M
INCOME TAX
Tax Provision
$15.4M$1.2M$-605.0K$-3.7M$-815.0K$518.0K$148.0K$337.0K$859.0K$740.0K
NET INCOME
Net Income
$-19.0M$-1.9M$-865.0K$-2.9M$-4.6M$-7.8M$-288.0K$-9.5M$-3.4M$-12.4M
Net Income (Continuing Operations)
$-19.0M$-1.9M$-865.0K$-2.9M$-4.6M$-7.8M$-288.0K$-9.5M$-3.4M$-12.4M
Net Income (Discontinued Operations)
$-19.0M$-1.9M$-865.0K$-2.9M$-4.6M$-7.8M$-288.0K$-9.5M$-3.4M$-12.4M
Net Income (Common Stockholders)
$-19.0M$-1.9M$-865.0K$-2.9M$-4.6M$-7.8M$-288.0K$-9.5M$-3.4M$-12.4M
Normalized Income
------------$1.2M----$-10.7M
TOTALS
Total Expenses
$-110.4M$-107.5M$-78.0M$-119.8M$114.3M$101.9M$116.8M$120.5M$110.4M$100.3M
SHARE & EPS DATA
Average Shares Outstanding
$33.6M$34.2M$34.8M$36.5M$37.8M$38.6M$40.3M$41.4M$42.4M$43.5M
Average Shares Outstanding (Diluted)
$33.6M$34.2M$34.8M$36.5M$37.8M$38.6M$40.3M$41.4M$42.4M$43.5M
Shares Outstanding
$34.0M$34.6M$35.6M$37.7M$38.3M$39.8M$41.2M$42.2M$43.4M$44.1M
Basic EPS
$-0.57$-0.13$-0.02$-0.08$-0.24$-0.20$-0.01$-0.23$-0.08$-0.28
Basic EPS (Continuing Operations)
$-0.57--$-0.06$-0.12$-0.24$-0.20$-0.01$-0.23$-0.08$-0.28
Diluted EPS
$-0.57$-0.13$-0.02$-0.08$-0.24$-0.20$-0.01$-0.23$-0.08$-0.28
Diluted EPS (Continuing Operations)
$-0.57--$-0.06$-0.12$-0.24------$-0.08$-0.28
OTHER METRICS
Acquisition Expense
------$-438.0K------------
Basic Discontinuous Operations
----$0.03$0.04------------
Diluted Discontinuous Operations
----$0.03$0.04------------
Gain On Sale Of Business
--$1.2M----$-228.0K------$403.0K--
Gains Loss On Disposal Of Discontinued Operations
----$1.2M$1.4M------------
Net Income Discontinuous Operations
----$1.2M$1.4M------------
Non Recurring Operation Expense
--------------$-233.0K----
Other Gand A
$19.8M$20.9M$17.5M$21.4M$22.8M$23.5M$24.3M$24.5M$22.8M$21.5M
Other Impairment Of Capital Assets
--------$-100.0K----------
Other Write Down
----------$787.0K--------
Rent And Landing Fees
$19.8M$20.9M$17.5M$21.4M------------
Selling Expense
$20.6M$20.5M$15.1M$24.4M$23.3M----------
Write Down
--$484.0K$-3.6M--------------
Restruct
$788.0K$-4.0K----$-1.4M$2.0M$1.3M$2.4M$391.0K$835.0K

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2HBIO$0.48+1.7%346.82K
3
4
5
6

Get Harvard Bioscience Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.